Clinical Trial: A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07244341) titled 'A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)' on Nov. 17.

Brief Summary: This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).

Study Start Date: Nov. 20

Study Type: INTERVENTIONAL

Condition: Metastatic Castration-resistant Prostate Cancer

Intervention: DRUG: Valemetostat

Dose Escalation Part: Valemetostat will be administered at escalating doses. Dose Expansion Part: Valemetostat will be administered at 2 or more dose level...